
Opinion|Videos|April 26, 2024
RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
3
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
4
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
5















































